These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25993615)

  • 1. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.
    Eder P; Michalak M; Katulska K; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K
    Sci Rep; 2015 May; 5():10223. PubMed ID: 25993615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
    Eder P; Katulska K; Krela-Kaźmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K; Łykowska-Szuber L
    Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-Bowel Crohn Disease Treated With Anti-Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes.
    Gallego JC; de Juan C; Echarri A; Lopez-de-Ullibarri I
    AJR Am J Roentgenol; 2019 Dec; 213(6):1240-1246. PubMed ID: 31414894
    [No Abstract]   [Full Text] [Related]  

  • 9. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment.
    Naganuma M; Okuda S; Hisamatsu T; Matsuoka K; Mori K; Hosoe N; Nakazato Y; Ogata H; Kanai T
    Abdom Radiol (NY); 2017 Jan; 42(1):141-151. PubMed ID: 27549100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease.
    Buisson A; Hordonneau C; Goutte M; Scanzi J; Goutorbe F; Klotz T; Boyer L; Pereira B; Bommelaer G
    Dig Liver Dis; 2016 Mar; 48(3):260-6. PubMed ID: 26699828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
    Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
    J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G; Herrmann KA; Louis E; Everett SM; Colombel JF; Rahier JF; Vanbeckevoort D; Meunier P; Tolan D; Ernst O; Rutgeerts P; Vermeire S; Aerden I; Oortwijn A; Ochsenkühn T
    J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease.
    Bhatnagar G; Dikaios N; Prezzi D; Vega R; Halligan S; Taylor SA
    Br J Radiol; 2015; 88(1055):20150547. PubMed ID: 26402217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.